PAYS stock touches 52-week low at $2.1 amid market challenges

In a challenging market environment, shares of 3Pea International Inc. (PAYS) have reached a 52-week low, dipping to $2.1. According to InvestingPro data, the company maintains strong fundamentals with 23.5% revenue growth and positive earnings of $0.07 per share in the last twelve months. The payment solutions company has faced significant headwinds over the past year, reflected in a substantial 1-year change with the stock price plummeting by 42.35%. While investors have shown concern, InvestingPro analysis suggests the stock is currently undervalued, with analyst targets ranging from $5.00 to $7.25 per share. Investors have shown concern as the company navigates through a period of uncertainty, which has been marked by this new low point in the stock’s performance. The decline to the 52-week low underscores the pressing need for the company to reassess its strategies and potentially pivot towards more sustainable growth avenues to regain investor confidence. Notably, two analysts have recently revised their earnings expectations upward for the upcoming period, suggesting potential positive developments ahead. Discover more insights and 6 additional ProTips for PAYS with a subscription to InvestingPro.

In other recent news, Paysign Inc. reported its fourth-quarter 2024 earnings, slightly surpassing expectations with a revenue of $15.61 million compared to the forecasted $15.45 million. The company experienced a significant 24% year-over-year increase in revenue, driven by strong performance in its plasma and patient affordability segments. Additionally, Paysign’s adjusted EBITDA rose by an impressive 43% year-over-year, underscoring improved operational efficiency. The company’s management has projected revenue for 2025 to range between $68.5 million and $70 million, indicating expected growth of 17.5% to 20%.

Paysign’s recent acquisition of Gamma Innovation LLC is anticipated to bolster its growth in the SaaS market. The acquisition aims to enhance Paysign’s capabilities in plasma donor and pharmaceutical patient engagement. DA Davidson reiterated its Buy rating for Paysign, maintaining a price target of $6.00, following the company’s strong earnings performance. The analyst from DA Davidson indicated that revised forecasts for Paysign will be released soon, reflecting the new financial data and management insights.

Paysign’s management expressed optimism for 2025, with expectations for the plasma segment to contribute significantly to total revenue. The company also plans to expand its patient affordability programs, which have already seen a substantial increase in revenue. Paysign’s strategic initiatives and recent financial results suggest potential opportunities for continued growth in the upcoming fiscal year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.